To further our understanding of the functional role of catecholaminergic systems in regulating hypothalamic corticotropin-releasing hormone (CRH) secretion, we assessed the direct effects of a multiplicity of catecholamine agonists and antagonists on hypothalamic CRH secretion. To accomplish this, we used an in vitro rat hypothalamic organ culture system in which CRH secretion from single explants was evaluated by a specific RIA (IRrCRH). Norepinephrine (NE) stimulated IR-rCRH secretion dose dependently, with peak effects in the nanomolar range. The effect of NE was antagonized by the mixed alpha antagonist phentolamine, the alpha 1 antagonist prazosin, and the alpha 2 antagonist yohimbine, but not by the beta blocker, L-propanolol. Compatible with these data were the findings that the alpha 1 agonist phenylephrine and the alpha 2 agonist clonidine both stimulated IR-rCRH secretion in a dose-dependent fashion. On the other hand, whereas the beta agonist, isoproterenol, caused a weak, non-dose-dependent increase in IR-rCRH secretion, this effect could not be antagonized by L-propanolol. Despite pretreatment with serotonin and acetylcholine antagonists, the effect of NE upon IR-rCRH secretion was undiminished, suggesting that NE-induced CRH secretion is not mediated by either neurotransmitter. On the other hand, pretreatment with gamma-aminobutyric acid (GABA) attenuated NE-induced IR-rCRH secretion. Whereas epinephrine (E) stimulated IR-rCRH secretion, this occurred only at higher concentrations, and was antagonized by phentolamine, but not by L-propanolol. (IR-rCRH). Norepinephrine (NE) stimulated IRrCRH secretion dose dependently, with peak effects in the nanomolar range. The effect of NE was antagonized by the mixed a antagonist phentolamine, the a, antagonist prazosin, and the a2 antagonist yohimbine, but not by the ,B blocker, L-propanolol. Compatible with these data were the findings that the a, agonist phenylephrine and the a2 agonist clonidine both stimulated IR-rCRH secretion in a dose-dependent fashion. On the other hand, whereas the fi agonist, isoproterenol, caused a weak, non-dose-dependent increase in IR-rCRH secretion, this effect could not be antagonized by L-propanolol. Despite pretreatment with serotonin and acetylcholine antagonists, the effect of NE upon IR-rCRH secretion was undiminished, suggesting that NE-induced CRH secretion is not mediated by either neurotransmitter. On the other hand, pretreatment with y-aminobutyric acid (GABA) attenuated NE-induced IR-rCRH secretion. Whereas epinephrine (E) stimulated IR-rCRH secretion, this occurred only at higher concentrations, and was antagonized by phentolamine, but not by L-propanolol. Dopamine (DA) had a weak stimulatory effect that could be antagonized by the DA, receptor antagonist, SCH 23390, but not by phentolamine.
Introduction
Catecholaminergic systems and especially the noredrenergic system have long been regarded as inhibitors of the hypotha-lamic-pituitary-adrenal (HPA)' axis (1) (2) (3) (4) (5) (6) (7) (8) . However, recent data obtained from experimental animals and humans indicate that the brainstem noradrenergic (i.e., locus coeruleus [LC] ) system and the HPA axis are both activated during physical (e.g., surgery, trauma, hemorrhage, and exercise) and emotional (e.g., depression, panic anxiety attacks, bereavement, examinations, and experimentally induced inescapable shock stress) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) . These data suggest that catecholamines (CA) stimulate the HPA axis at the pituitary and/or hypothalamic/suprahypothalamic levels. There is general agreement that norepinephrine (NE) and epinephrine (E) are capable of stimulating pituitary ACTH in vitro (26) and that the stimulatory effect of both CA is additive to the stimulatory effect of corticotropin-releasing hormone (CRH) (26, 27) .
On the other hand, both anatomical and functional studies indicate that CA also act at the hypothalamic site of the HPA axis. It has been shown that the parvocellular division of the paraventricular nucleus (PVN), which contains the majority of the CRH-positive perikarya in the hypothalamus (28) (29) (30) (31) , receives copious catecholaminergic innervations originating from the brainstem catecholaminergic regions (32) (33) (34) . Furthermore, direct synaptic interactions between catecholaminergic terminals and CRH neurons have been demonstrated (35) . Inferences from pharmacological studies regarding the functional nature (inhibitory or stimulatory) of these afferent noradrenergic fibers to the hypothalamic PVN remain, however, controversial. Many pharmacological studies have yielded data supporting a central inhibitory effect of CA on CRH secretion (36) (37) (38) (39) (40) . Alternatively, other studies provide evidence for a stimulatory effect of CAs on the central component of the HPA axis (41) (42) (43) (44) (45) (46) (47) (48) (49) .
This study was performed to evaluate the effects of a multiplicity of catecholamine agonists and antagonists on hypothalamic CRH secretion. To accomplish this, we used an in vitro hypothalamic organ culture system, in which immunoreactive rat CRH (IR-rCRH) secretion was measured directly from single explants. We also attempted to explore the potential interaction between NE and other neurotransmitters such as serotonin (5HT), acetylcholine, and gamma-aminobutyric acid (GABA) on CRH secretion. 1 . Abbreviations used in this paper: ANOVA, analysis of variance; AVP, arginine vasopressin; CA, catecholamines; CR, corticotropin releasing; CRH, corticotropin-releasing hormone; DA, dopamine; DHPG, 3,4 dihydroxyphenylethyleneglycol; E, epinephrine; 5HT, serotonin; GABA, gamma-aminobutyric acid; HPA, hypothalamic-pituitary-adrenal axis; ICV, intracerebroventricular; IR-rCRH, immunoreactive rat corticotropin-releasing hormone; LC, locus coeruleus; MSH, melanocyte-stimulating hormone; NE, norepinephrine; QT, oxytocin; PVN, paraventricular nucleus; 6-OHDA, 6-hydroxydopamine; VIP, vasoactive intestinal peptide; VNAB, ventral noradrenergic ascending bundle.
Methods
Materials. NE Experimental protocols. To determine the effects of NE, clonidine, phenylephrine, E, isoproterenol, and DA, the hypothalami were incubated in plain medium in the first three wells (basal IR-rCRH concentration) and exposed to graded concentration ofthese substances in the next two wells (stimulated IR-rCRH concentration). Controls for this set ofexperiments were obtained exposing the hypothalami to medium with no test substance. To evaluate the effects of specific antagonists, the hypothalami were incubated in plain medium in the first two wells (basal IR-rCRH concentration). In the third, fourth, and fifth wells the antagonist(s) were present, whereas in the fourth and fifth wells the stimulant was added (stimulated IR-rCRH concentration). Finally, to determine the effect of GABA on NE-induced IR-rCRH secretion, GABA was added during the last hour of preincubation and throughout the experiment conducted according to protocol 1.
CRH radioimmunoassay. Medium concentration of CRH was measured directly without prior extraction by RIA, using a specific anti-rCRH serum (TS-3) obtained from rabbits immunized with synthetic rCRH conjugated to BSA. 251-rCRH, prepared by the chloramine T method (50) (51) . Logarithmic transformation of the data was applied to correct for heteroscedasticity, detected by the Bartlett test (52) .
Results
Basal IR-rCRH secretion in plain medium was 48.3±5.7 pg/ hypothalamus per 0.4 ml per 20 min, whereas mean±SE basal IR-rCRH secretion of all the experiments performed for this study was 49.3±5.3 pg/hypothalamus per 0.4 ml per 20 min (n = 33 experiments, m = 432 measurements). NE stimulated IR-rCRH release in a dose-dependent fashion (Fig. 1) . 10-12 M NE was the lowest concentration capable ofproducing a significant IR-rCRH secretion, 49±39% above baseline (P < 0.05 vs. (Fig. 2) . Phentolamine, an a, and a2 receptor antagonist, profoundly antagonized NE-induced IR-rCRH release at both (10-9 and l0-I M) concentrations used 60±19 and 14+1 1%, above baseline, respectively, vs. 349±85%; P < 0.05 for both concentra- tions; Duncan test (Figs. 3 and 4) . Phenylephrine, an a, adrenergic agonist, stimulated IR-rCRH secretion in a dose-dependent fashion (Fig. 3 A) . The lowest stimulatory concentration (10-" M) induced an IR-rCRH rise of 55±24% above baseline (P < 0.05 vs. concentration zero; Duncan test). Clonidine, an a2 receptor agonist (Fig. 3 B) , also stimulated IR-rCRH secretion in a dose-dependent fashion, with 10-12 M being the lowest stimulatory concentration (60±21% increase above baseline; P < 0.05 vs. concentration zero; Duncan test). The greater potency of clonidine in inducing IR-rCRH secretion compared with the a, agonist phenylephrine, is compatible with the greater antagonism of a2 versus a, antagonists.
Isoproterenol, a 1, and 12 agonist, had a weak, non-dose-dependent stimulatory effect upon IR-rCRH secretion (Fig. 4) .
This stimulatory action of isoproterenol could not be antagonized by propanolol or phentolamine, suggesting a nonspecific rather than receptor-mediated mechanism (Fig. 4, inset) .
To determine whether other neurotransmitter systems modulated the a-adrenergic-mediated NE-induced IR-CRH secretion, we assessed the effects of antagonists to 5HT type 2 (ritanserin), muscarinic (atropine), and nicotinic (hexamethonium) receptors. We also assessed the effect of the inhibitory neurotransmitter GABA upon NE-induced IR-CRH secretion (Fig. 5) . Neither ritanserin nor atropine and hexamethonium, We also determined the effects of other catecholamines; namely, E and DA, on in vitro IR-rCRH secretion. E stimulated IR-rCRH secretion in a dose-dependent fashion (Fig. 6 ). 10-11 M E was the minimal stimulatory concentration (P < 0.05 vs. concentration zero; Duncan test). Maximal stimulatory effect of E upon IR-rCRH secretion was obtained at concentrations of l0-9 and 10-7 M (P < 0.05 vs. 10-" M concen- (Fig. 7, inset) , suggesting that the stimulatory effect of DA upon IR-rCRH (19) . Weiss pro- posed that this effect of NE agonists on LC firing rates was mediated by an interaction between NE and presynaptic a2 inhibitory receptors in the region of the LC. The latter are the only adrenergic receptors known to reside in this area (55). Hence, the ICV NE agonist-induced decrease ofadrenocortical activity could be mediated by inhibition of LC-mediated stimulation of the PVN (54) . Conversely, the systemic or ICV administration of NE antagonists could increase adrenocortical function by enhancing LC activation of hypothalamic CRH neurons (56) . Another possible factor to be considered in interpreting the findings of these studies is the use of anesthetized animals. It is known that anesthetic agents can change the magnitude and/or direction of central nervous system response to physical, chemical, or electrical stimuli ( 15, 57) . All of these studies also assessed hypothalamic CRH secretion indirectly, by measuring plasma ACTH and/or glucocorticoid concentrations as endpoints.
Inhibitory effects of CAs on the HPA axis also have been suggested on the basis of in vitro studies performed with hypothalamic explants (36) (37) (38) (39) (40) . However, most of these studies (36) (37) (38) (39) measured corticotropin-releasing (CR) bioactivity rather than CRH as endpoint and it is now known that several hypothalamic factors exert CR bioactivity. These include AVP, OT, 5HT, E, and VIP (58) . Only one prior study, conducted by Suda et (49) .
In conclusion, our hypothalamic organ culture system has allowed us to study the effects of many catecholamine agonists and antagonists upon hypothalamic CRH secretion. Although our experimental model used deafferented and relatively longterm incubated hypothalami, catecholamines and norepinephrine in particular, reproducibly stimulated CRH secretion. A possible in vivo stimulatory NE effect on hypothalamic CRH secretion may be of interest in light ofrecent data showing that CRH administration to awake, unrestrained rats markedly increases the LC firing rate (61, 62) . These data, taken together, suggest that hypothalamic CRH neurons and NE neurons in regions such as the LC may participate in a mutually reinforcing positive feedback loop. These observations may be pertinent to stressful situations and psychiatric conditions, like depression and panic disorder, characterized by activation of both the LC-NE and the CRH systems (63) .
